SCHEMBL5210674

SCHEMBL5210674

Cc1ccc(C(=O)O)c(NC(=O)Cc2c(C)[nH]c3ccc(Cl)cc23)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.54
▸ MEN1 O00255 6/20 0.53
▸ KMT2A Q03164 6/20 0.53
▸ KDM4E B2RXH2 5/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ GAA P10253 1/20 0.53
▸ POLB P06746 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ LMNA P02545 1/20 0.46
▸ PRSS1 P07477 1/20 0.45
▸ PRSS2 P07478 1/20 0.45
▸ PRSS3 P35030 1/20 0.45
▸ KLK6 Q92876 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ NTRK1 P04629 1/20 0.44
▸ ACLY P53396 1/20 0.43
▸ PPARG P37231 1/20 0.43
▸ PPARA Q07869 1/20 0.43
▸ ADRA2A P08913 1/20 0.43
▸ ADRA2B P18089 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208935 0.86 MEN1 (0.62) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5211697 0.86 MAPT (0.55) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5214528 0.85 AKR1C2 (0.61) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5207058 0.82 MAPT (0.46) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5209948 0.80 MAPT (0.62) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5274070 0.77 AKR1C2 (0.58) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5205838 0.77 AKR1C2 (0.61) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL1757962 0.76 KDM4E (0.73) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5213945 0.76 KDM4E (0.53) MAPTKDM4EALDH1A1SMN1; SMN2ACLY
SCHEMBL8806095 0.76 NTRK1 (0.53) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 — — US claimed
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 — — US disclosed
EP-1343757-B1 INDOLE DERIVATIVES GLAXO GROUP LTD (GB) 2007-02-14 — — EP disclosed
US-20040092569-A1 Indole derivatives GLAXO GROUP LIMITED (GB) 2004-05-13 — — US disclosed
EP-1343757-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-09-17 — — EP disclosed
WO-2002050031-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2002-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092569-A1 Indole derivatives PTGER4, PTGER1, TRPV4 MAPT 788/4885MEN1 2074/4885KMT2A 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback